Risk Factors and Prognosis of Patients with Acute Leukemia and Intracranial Hemorrhage
Latife Salame1, Carlos Cantu-Brito1, Erwin Chiquete1, David Medina-Julio2
1Department of Neurology and Psychiatry, INCMNSZ, 2Internal Medicine, General Hospital "Dr. Manuel Gea González"
Objective:

To determine the risk factors associated with intracranial hemorrhage (ICH) in patients with acute leukemia (AL), verify the thrombocytopenia threshold that increases the risk of ICH, describe the prognosis, and propose preventive measures for these subjects. 

Background:
Case series indicate that 60 to 80% of patients with AL develop thrombocytopenia, increasing the risk of ICH. Several other factors may contribute to the risk of ICH in this population.
Design/Methods:

A case-control, retrospective, single-center study was conducted. The medical records of 547 patients between July 1999 and June 2024 were reviewed. A univariate logistic regression analysis was performed to evaluate the correlation of various risk factors with ICH in patients with AL. A descriptive analysis of the prognosis was performed.

Results:

Nine percent of patients had ICH. Women accounted for a higher proportion of ICH cases (57.1%), but the difference in gender distribution was not significant. Most ICH cases were observed in patients with acute myeloid leukemia (42.9%) and acute lymphoblastic leukemia (40.8%). Identified risk factors for ICH were: hyperleukocytosis (OR= 3.504, 95% CI: 1.658–7.405), infection at the time of ICH (OR= 2.255, 95% CI: 1.091–4.66), smoking (OR= 2.648, 95% CI: 1.198–5.856), and lower platelet counts (0-4999 /µL: OR= 2.255, 95% CI: 1.091–4.66), identifying a platelet threshold of 5000 /µL. Patients who experienced ICH had a higher mortality rate (79.6% vs. 63%). Most ICH patients had an unfavorable functional prognosis on the modified Rankin scale, with 65.3% achieving a score of 6 (death). The average survival after ICH was 49 days.

Conclusions:

This is the first Latin American case series published on ICH in AL. We identified modifiable risk factors that could be treated to prevent ICH. Strategies such as platelet transfusions starting from 5000 /µL and proactive infection management, could improve outcomes.

10.1212/WNL.0000000000210743
Disclaimer: Abstracts were not reviewed by Neurology® and do not reflect the views of Neurology® editors or staff.